Objective
ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel
concept that precludes the development of viral resistance and ensures efficacy against
upcoming pandemic influenza strains. Viral replication is known to depend on multiple host
factors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU will
aim at drugs interfering with host-response pathways. The concept of drugs targeting human
factors, established in treatment of other diseases, has yet not been sufficiently explored for
treatment of viral infections, although it bears compelling advantages over conventional
antiviral therapies: (i) the avoidance of viral escape mutants and (ii) the broad coverage
against unprecedented viral variants.
ANTIFLU aims to fully exploit this potent approach to fill critical gaps in our current treatment
and prevention options against seasonal and pandemic influenza virus infections. By building
upon an existing panel of potent human targets and firm knowledge derived from FP6 project
RIGHT, an interdisciplinary consortium will pursue the identification and validation of small
molecule ligands and inhibitory RNA molecules effective against influenza infection.
Promising modulators will form the basis to generate lead molecules that will be further
refined to yield clinically applicable therapeutics. Initial preclinical studies will aim at providing
proof of concept in animal models, safety and toxicology profiles. They will allow initiating
complete clinical trials immediately after the phase of FP7 support, thanks to the commitment
already taken by investors from the private sector. The consortium includes several SMEs,
internationally renowned research groups and clinical institutions with extensive experience
in anti-influenza treatment and clinical trials. An already agreed common exploitation model
will provide a smooth route to market and optimal use of the project results.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses influenza
- natural sciences biological sciences genetics RNA
- medical and health sciences basic medicine toxicology
- social sciences psychology ergonomics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-INFLUENZA-2010
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
80539 MUNCHEN
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.